NCT02931136

Early Diagnosis and Early Treatment of Alzheimer's Disease Based on Senile Plaque Imaging

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 300 (estimated)
• Sponsor: Shanghai Mental Health Center · Academic / Other
• Sex: All
• Age: 55 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is based on the Flutemetamol-PET senile plaque imaging to investigate the peripheral blood biochemical and brain MRI imaging biomarkers and to research completely independent intellectual property rights neuropsychological test tool for the MCI due to AD. At the same time, the investigators will study the efficacy and safety of early treatment of MCI due to AD by Huperzine A in 52 weeks.

Detailed description

This is a randmized, double-blind, placebo-controll study.

Conditions

• Mild Cognitive Impairment
• Biomarker
• Diagnosis
• Treatment

Interventions

Type	Name	Description
DRUG	Huperzine A	The participants will treatment by the Huperzine A 200 ug/day in 52 weeks.
DRUG	Placebo	The participants will treatment by the placebo in 52 weeks.

Timeline

• Start date: 2019-11-01
• Primary completion: 2024-12-01
• Completion: 2025-12-01
• First posted: 2016-10-12
• Last updated: 2019-04-16

Locations

1 site across 1 country: China